AZN - Ticker AI Digest

AstraZeneca PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (AZN) 1
AZN 14:01
AstraZeneca PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 2
AZN 06:01
AstraZeneca PLC
Imfinzi approved in US for early gastric cancer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready to help!
AZN 06:01
AstraZeneca PLC
Koselugo (selumetinib) approved in the US
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZenecas Alexion Rare Disease unit has received U.S. FDA approval for **Koselugo (selumetinib)**, an oral MEK inhibitor, to treat **adults with neurofibromatosis type 1 (NF1)** who have symptomatic, inoperable plexiform neurofibromas (PN). This approval is based on positive results from the **KOMET Phase III trial**, which demonstrated a **20% overall response rate** in tumor size reduction compared to 5% with placebo. NF1 is a rare genetic condition causing non-malignant tumors (PN) that can lead to pain, disfigurement, and other debilitating symptoms. Koselugo, already approved for pediatric NF1 patients, has now expanded its use to adults, offering continuity of care across the disease journey. The drug has also been recently approved in the EU, Japan, and other countries for adult NF1 patients. This milestone underscores Koselugos transformative impact on NF1 treatment, supported by over a decade of clinical evidence and collaboration among scientists, clinicians, industry, and the NF community.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 2
AZN 10:01
AstraZeneca PLC
Director/PDMR Shareholding
AZN 14:01
AstraZeneca PLC
Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
AZN 06:01
AstraZeneca PLC
9M and Q3 2025 results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
## AstraZeneca 9M and Q3 2025 Results Summary
**Strong Performance and Pipeline Progress:**
AstraZenecas 9M and Q3 2025 results showcase continued strong commercial performance and significant pipeline advancements.
**Financial Highlights (9M 2025)**
* **Revenue Growth** Total revenue increased by 11% to $43.236 billion, driven by growth across all Therapy Areas, particularly Oncology (16%) and R&I (13%).
* **Core EPS Growth** Core EPS rose by 15% to $7.04, reflecting improved profitability.
* **Operating Profit Increase** Core operating profit grew by 13%, demonstrating operational efficiency.
**Pipeline Achievements**
* **16 Positive Phase III Readouts** AstraZeneca announced 16 positive Phase III trial results, including significant advancements in hypertension (baxdrostat), breast cancer (Enhertu, Datroway), and other areas.
* **31 Regulatory Approvals** The company secured 31 approvals in major regions for various medicines, expanding patient access.
* **Strong Oncology Pipeline** Oncology remains a key focus with 16 positive Phase III readouts and approvals for medicines like Enhertu, Datroway, and Imfinzi.
**Strategic Initiatives**
* **US Expansion** AstraZeneca is investing heavily in the US, including a $4.5 billion manufacturing facility in Virginia and a historic agreement with the US government to lower medicine costs.
* **Acquisition of SixPeaks Bio AG** This acquisition strengthens AstraZenecas position in weight management therapies.
* **Koselugo Agreement with Merck** A simplified agreement for Koselugo development and commercialization enhances focus and efficiency.
**Future Outlook**
* **Reiterated Guidance** AstraZeneca maintains its Total Revenue and Core EPS guidance for FY 2025, expecting high single-digit revenue growth and low double-digit Core EPS growth.
* **Sustainability Leadership** Recognized for sustainability efforts, AstraZeneca ranks highly in global sustainability rankings.
**Key Takeaways**
AstraZenecas 9M and Q3 2025 results demonstrate robust financial performance, significant pipeline progress, and strategic initiatives aimed at long-term growth. The companys focus on innovation, geographic expansion, and sustainability positions it well for continued success in the pharmaceutical industry.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 2
AZN 14:01
AstraZeneca PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
AZN 14:01
AstraZeneca PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 10
AZN 14:01
AstraZeneca PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
AZN 14:06
AstraZeneca PLC
Block listing Interim Review
AZN 14:01
AstraZeneca PLC
Total Voting Rights
AZN 06:01
AstraZeneca PLC
Imfinzi approved in US for early gastric cancer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready to help!
AZN 06:01
AstraZeneca PLC
AstraZeneca manufacturing investment in Maryland
AZN 06:01
AstraZeneca PLC
Koselugo (selumetinib) approved in the US
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
AstraZenecas Alexion Rare Disease unit has received U.S. FDA approval for **Koselugo (selumetinib)**, an oral MEK inhibitor, to treat **adults with neurofibromatosis type 1 (NF1)** who have symptomatic, inoperable plexiform neurofibromas (PN). This approval is based on positive results from the **KOMET Phase III trial**, which demonstrated a **20% overall response rate** in tumor size reduction compared to 5% with placebo. NF1 is a rare genetic condition causing non-malignant tumors (PN) that can lead to pain, disfigurement, and other debilitating symptoms. Koselugo, already approved for pediatric NF1 patients, has now expanded its use to adults, offering continuity of care across the disease journey. The drug has also been recently approved in the EU, Japan, and other countries for adult NF1 patients. This milestone underscores Koselugos transformative impact on NF1 treatment, supported by over a decade of clinical evidence and collaboration among scientists, clinicians, industry, and the NF community.
AZN 14:01
AstraZeneca PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
AZN 10:01
AstraZeneca PLC
Director/PDMR Shareholding
AZN 14:01
AstraZeneca PLC
Director/PDMR Shareholding
AZN 06:01
AstraZeneca PLC
9M and Q3 2025 results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
## AstraZeneca 9M and Q3 2025 Results Summary
**Strong Performance and Pipeline Progress:**
AstraZenecas 9M and Q3 2025 results showcase continued strong commercial performance and significant pipeline advancements.
**Financial Highlights (9M 2025)**
* **Revenue Growth** Total revenue increased by 11% to $43.236 billion, driven by growth across all Therapy Areas, particularly Oncology (16%) and R&I (13%).
* **Core EPS Growth** Core EPS rose by 15% to $7.04, reflecting improved profitability.
* **Operating Profit Increase** Core operating profit grew by 13%, demonstrating operational efficiency.
**Pipeline Achievements**
* **16 Positive Phase III Readouts** AstraZeneca announced 16 positive Phase III trial results, including significant advancements in hypertension (baxdrostat), breast cancer (Enhertu, Datroway), and other areas.
* **31 Regulatory Approvals** The company secured 31 approvals in major regions for various medicines, expanding patient access.
* **Strong Oncology Pipeline** Oncology remains a key focus with 16 positive Phase III readouts and approvals for medicines like Enhertu, Datroway, and Imfinzi.
**Strategic Initiatives**
* **US Expansion** AstraZeneca is investing heavily in the US, including a $4.5 billion manufacturing facility in Virginia and a historic agreement with the US government to lower medicine costs.
* **Acquisition of SixPeaks Bio AG** This acquisition strengthens AstraZenecas position in weight management therapies.
* **Koselugo Agreement with Merck** A simplified agreement for Koselugo development and commercialization enhances focus and efficiency.
**Future Outlook**
* **Reiterated Guidance** AstraZeneca maintains its Total Revenue and Core EPS guidance for FY 2025, expecting high single-digit revenue growth and low double-digit Core EPS growth.
* **Sustainability Leadership** Recognized for sustainability efforts, AstraZeneca ranks highly in global sustainability rankings.
**Key Takeaways**
AstraZenecas 9M and Q3 2025 results demonstrate robust financial performance, significant pipeline progress, and strategic initiatives aimed at long-term growth. The companys focus on innovation, geographic expansion, and sustainability positions it well for continued success in the pharmaceutical industry.

AI Crunch

Single-Ticker AI Crunch
AZN signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for AstraZeneca PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AZN AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for AZN on 2025-12-04.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
231353303040
Enterprise Value
188046885670
Public Float
99.52
Broker Target
16212.231
Shares Out
1550833276
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB0009895292
Market
LSE - MAIN MARKET
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
2.36
Ex Divi
2026-02-19
Earnings Date
2026-02-05
Net Debt
23911000000.0
Cash
5711000000.0
EPS
4.89
Net Income
10225000000.0
Revenue
58739000000.0
Enterprise Value
188046885670
Trailing PE
30.5072
Forward PE
19.2308
Price Sales TTM
3.9387
Price Book MRQ
6.2017
EV Revenue
5.6989
EV EBITDA
17.1614

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
4.9735
Institutions As Of
2025-12-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
5
Sale Director Dealing
2
Purchase TR1
3
Sale TR1
3
Broker Coverage Rows
38
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit AZN.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-12-04 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
AstraZeneca PLC has fresh news flow feeding the chart narrative.
AI Charts Studio
AZN Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-12-04 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 7.46%
RSI Gauge
Price Change
AI Forecast